Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bayesian model of Calcium edetate de sodium plasma clearance for GFR estimation
2014-003496-29Phase 3Active
- Sponsor
- CHU de Limoges
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edetate calcium disodium in chronic kidney disease (CKD), sponsored by CHU de Limoges. Primary endpoint: DFGBay (Bayesian GFR based on Calcium edetate de sodium plasma clearance). Started Jan 2015; status: active.
02
Drugs
edetate calcium disodium
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2014-003496-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003496-29.